Cargando…
S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428233/ http://dx.doi.org/10.1097/01.HS9.0000967968.05170.e0 |
| _version_ | 1785090418289934336 |
|---|---|
| author | Hanna, Rabi Frangoul, Haydar Mckinney, Christopher Pineiro, Luis Mapara, Markus Chang, Kai-Hsin Jaskolka, Michael Kim, Keunpyo Rizk, Maha Afonja, Olubunmi Lawal, Adebayo Walters, Mark |
| author_facet | Hanna, Rabi Frangoul, Haydar Mckinney, Christopher Pineiro, Luis Mapara, Markus Chang, Kai-Hsin Jaskolka, Michael Kim, Keunpyo Rizk, Maha Afonja, Olubunmi Lawal, Adebayo Walters, Mark |
| author_sort | Hanna, Rabi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428233 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282332023-08-17 S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME Hanna, Rabi Frangoul, Haydar Mckinney, Christopher Pineiro, Luis Mapara, Markus Chang, Kai-Hsin Jaskolka, Michael Kim, Keunpyo Rizk, Maha Afonja, Olubunmi Lawal, Adebayo Walters, Mark Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428233/ http://dx.doi.org/10.1097/01.HS9.0000967968.05170.e0 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Hanna, Rabi Frangoul, Haydar Mckinney, Christopher Pineiro, Luis Mapara, Markus Chang, Kai-Hsin Jaskolka, Michael Kim, Keunpyo Rizk, Maha Afonja, Olubunmi Lawal, Adebayo Walters, Mark S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_full | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_fullStr | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_full_unstemmed | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_short | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_sort | s264: edit-301 shows promising preliminary safety and efficacy results in the phase i/ii clinical trial (ruby) of patients with severe sickle cell disease using highly specific and efficient ascas12a enzyme |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428233/ http://dx.doi.org/10.1097/01.HS9.0000967968.05170.e0 |
| work_keys_str_mv | AT hannarabi s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT frangoulhaydar s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT mckinneychristopher s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT pineiroluis s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT maparamarkus s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT changkaihsin s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT jaskolkamichael s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT kimkeunpyo s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT rizkmaha s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT afonjaolubunmi s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT lawaladebayo s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT waltersmark s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme |